Article: article from journal or magazin.
Case report (case report): feedback on an observation with a short commentary.
Efficiency and safety of bosentan in child C cirrhosis with portopulmonary hypertension and renal insufficiency.
European Journal of Gastroenterology and Hepatology
Publication types: Case Reports ; Journal Article
Bosentan has lately been described as a successful therapeutic agent for portopulmonary hypertension consecutive to child A cirrhosis. This is the first report of the effect of this substance with advanced liver cirrhosis (child C) and renal insufficiency. Low doses of bosentan (initially twice 31.25 mg/day and then 62.5 mg/day) increased cardiac output and allowed correction of renal insufficiency; it allowed one to stop the requirement of oxygen and not only improved the 6-min walking test by more than 400 m, but also decreased the severity of the liver cirrhosis to child B stadium. This suggests that patients, who would be excluded from a liver transplantation program because of their portopulmonary hypertension, could profit from a careful therapy with bosentan.
Adult, Antihypertensive Agents/therapeutic use, Humans, Hypertension, Portal/drug therapy, Hypertension, Portal/etiology, Hypertension, Pulmonary/drug therapy, Hypertension, Pulmonary/etiology, Liver Cirrhosis/complications, Male, Renal Insufficiency/complications, Sulfonamides/therapeutic use, Treatment Outcome
Web of science
Last modification date